Perceptions of Neighbourhood Walkability

Summary

The planning and development of liveable, vibrant, neighbourhoods has gained more interest over the past few decades as a way to increase physical activity, prevent chronic diseases, and promote health and wellbeing. There is however, mixed views and perspectives between homebuyers and sellers, real estate professionals, and community developers about what features contribute to a livable, vibrant, and healthy neighbourhood.

Researchers at the University of Calgary are recruiting participants for a study exploring perceptions of neighbourhood “walkability”, “bike-ability”, “vibrancy”, “livability”, and “health” in Alberta among new homebuyers, Real Estate Professionals, and land developers. The findings from this study will be used to identify commonalities and differences in the terminology and language used by these groups to describe neighbourhoods and communities. We hope to develop universal terminology that can be used by professional, trade and academic groups and the general public when describing neighbourhoods and communities.

Eligibility

Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 20 to 80

Accepts healthy participants: Yes

Inclusion criteria:

Participants from the following categories who live in Calgary, Edmonton, and Lethbridge will be included in this study:

1. Home buyers who have moved to a newly purchased home within the past two months
2. Residential Real Estate Professionals
3. Residential land developers

Exclusion criteria:

1. Individuals living outside of Calgary, Edmonton, or Lethbridge
2. Home owners who have been living in their home for more than two months
3. Commercial Real Estate Professionals
4. Commercial land developers

Participate

Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

If you are interested in participating in the study, please contact the Research Coordinator Dalia Ghoneim via email or telephone to schedule an interview.

Principal investigator:

Gavin McCormack

Clinical trial:

No

REB-ID:

REB19-1069